Brandon Capital
Brandon Capital Partners, established in 2007, is a Melbourne-based venture capital firm with additional offices in California and Sydney. It focuses on seed and venture capital investments in innovative life science, healthcare, and technology companies across Australia and New Zealand. The firm's strategy involves working closely with entrepreneurs to build and grow businesses, creating value for both the entrepreneurs and their investors, primarily Australia's leading superannuation funds. Brandon Capital Partners' investment preferences span across pharmaceuticals, biotechnology, healthcare devices, life sciences, digital health, healthtech, oncology, and manufacturing sectors.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in New Zealand
Heart Metabolics
Series A in 2014
Heart Metabolics Limited is a pharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, making it harder for blood to leave the heart and often leading to heart failure or sudden death. With over 100,000 cases in the United States alone, HCM can be particularly severe in young adults and athletes. Current cardiovascular drugs do not help all patients, highlighting a significant medical need. Heart Metabolics is addressing this by developing perhexiline, an approved drug in Australia and New Zealand for angina, as a therapeutic for all types of HCM. The company plans to conduct clinical trials in the U.S. and seek FDA approval for perhexiline as an orphan drug, which it has already designated.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.